Summary:
The Korean SME has developed and commercialized an innovative software-based digital therapy for brain disorders such as dementia.Through their medical data platform, it is possible to collect and analyze each patient’s lifelog biometric data. With this data, individualized solutions and services can be provided.
The company aims to expand to the EU countries with local partners to localize, commercialize and integrate the software, through licence or commercial agency agreements.
Description:
The South Korea based company, founded in 2017, developed a software based digital therapy for mediating multi-domain to prevent dementia with the support from the Ministry of Health and Welfare and the Korea Health Industry Development Institute. The company has recently commercialized the product in January 2021.
The digital therapy is a third-generation treatment that can manage disorders without taking medicine or syringes, allowing patients to diagnose and treat themselves using mobile applications or virtual reality.
This is advanced software that provides evidence-based therapeutic interventions for patients to prevent, manage, and treat diseases or disorders. It delays and prevents dementia with an algorithm that improves cognitive function based on artificial intelligence.
This digital therapy consists of vascular risk factor management, cognitive training, exercise, nutritional education, and motivation programs. The program can be mainly used for Alzheimer's and Parkinson's disease, and stroke.
The therapy is already on the local market and they are now ready to grow internationally. Therefore, the SME would like to establish new partnerships with EU based companies. Favoured are long-term partnerships through commercial agency or possibly licence agreements.
Type (e.g. company, R&D institution…), field of industry and Role of Partner Sought:
The company is looking for partners to localize, commercialize and integrate the software in EU countries. Ideally, the partner should have experience in working with medical equipment and have links with relative medical centers, research centers and hospitals.
As the therapy program is currently developed and optimized for Korean language and culture, the localization process should be taken as a first step. Once the localization process is completed, the commercial agencies or integrators should be capable of promoting the program through relevant market channels.
Stage of Development:
Already on the market
IPR Status:
Patents granted
External code:
BOKR20211006001
